Monjuvi Side Effects

Generic name: tafasitamab

Medically reviewed by Drugs.com. Last updated on Jun 6, 2024.

Note: This document provides detailed information about Monjuvi.

Applies to tafasitamab: intravenous powder for solution Side Effects associated with tafasitamab. Some dosage forms listed on this page may not apply specifically to the brand name Monjuvi.

Applies to tafasitamab: intravenous powder for solution.

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood tests are needed to check for unwanted effects.

Receiving this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant during treatment and for at least 3 months after the last dose. If you think you have become pregnant while using the medicine, tell your doctor right away.

This medicine may cause an infusion reaction, which can be life-threatening and requires immediate medical attention. Tell your doctor or nurse right away if you have a fever, chills, headache, feeling of warmth, redness of the face, neck, arms and occasionally, upper chest, trouble breathing, lightheadedness, fainting, or chest pain within a few hours after you receive it.

This medicine lowers the number of some types of blood cells in your body. Because of this, you may bleed or get infections more easily. To help with these problems, avoid being near people who are sick or have infections. Wash your hands often. Stay away from rough sports or other situations where you could be bruised, cut, or injured. Brush and floss your teeth gently. Be careful when using sharp objects, including razors and fingernail clippers.

Serious side effects of Monjuvi

Along with its needed effects, tafasitamab (the active ingredient contained in Monjuvi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking tafasitamab:

Other side effects of Monjuvi

Some side effects of tafasitamab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to tafasitamab: intravenous powder for injection.

General adverse events

The most common adverse reactions (20% or greater) were infections, neutropenia, fatigue, asthenia, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite.^[Ref]

Immunologic

• Very common (10% or more): Infections (73%), Grade 3 or higher infection (30%)
• Common (1% to 10%): Sepsis, hypogammaglobulinemia
• Frequency not reported: Potential immunogenicity^[Ref]

Local

• Common (1% to 10%): Infusion related reactions (IRRs) (e.g., chills, flushing, dyspnea, hypertension)^[Ref]

Musculoskeletal

• Very common (10% or more): Back pain (19%), muscle spasms (15%)
• Common (1% to 10%): Arthralgia, pain in extremity, musculoskeletal pain^[Ref]

Metabolic

• Very common (10% or more): Glucose increased (49%), calcium decreased (47%), gamma glutamyl transferase increased (34%), albumin decreased (26%), magnesium decreased (22%), anorexia (22%), urate increased (20%), phosphate decreased (20%), hypokalemia (19%), decreased appetite
• Common (1% to 10%): Weight loss, C-reactive protein increased^[Ref]

Genitourinary

• Very common (10% or more): Urinary tract infection (e.g., urinary tract infection, Escherichia urinary tract infection, urinary tract infection bacterial, urinary tract infection enterococcal) (17%)^[Ref]

Hepatic

• Very common (10% or more): Aspartate aminotransferase increased (20%)
• Common (1% to 10%): Hyperbilirubinemia, transaminases increased (includes ALT and/or AST increased)^[Ref]

Oncologic

• Common (1% to 10%): Basal cell carcinoma^[Ref]

Respiratory

• Very common (10% or more): Cough (26%), respiratory tract infection (e.g., lower respiratory tract infection, upper respiratory tract infection, respiratory tract infection) (24%), bronchitis (16%), dyspnea (12%), nasopharyngitis (10%), pneumonia (10%)
• Common (1% to 10%): Nasal congestion, exacerbation of obstructive pulmonary disease^[Ref]

Other

• Very common (10% or more): Fatigue/asthenia (38%), pyrexia (24%), peripheral edema (24%)^[Ref]

Hematologic

• Very common (10% or more): Neutropenia (51%), activated partial thromboplastin time increased (46%), anemia (36%), thrombocytopenia (31%), febrile neutropenia (12%), leukopenia
• Common (1% to 10%): Lymphopenia^[Ref]

Nervous system

• Common (1% to 10%): Headache, paresthesia, dysgeusia^[Ref]

Renal

• Very common (10% or more): Creatinine increased (20%)^[Ref]

Dermatologic

• Common (1% to 10%): Erythema, alopecia, hyperhidrosis, rash (includes different types of rash, e.g. rash, rash maculopapular, rash pruritic, rash erythematous)^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (36%), constipation (17%), nausea (15%), vomiting (15%), abdominal pain
• Common (1% to 10%): Mucosal inflammation^[Ref]

See also:

Frequently asked questions

• How does Monjuvi work?
• How is Monjuvi given / administered?
• What is the success rate of Monjuvi?

Further information

Monjuvi side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer